In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria

被引:42
|
作者
Goldstein, Ellie J. C. [1 ,2 ]
Citron, Diane M. [1 ]
Tyrrell, Kerin L. [1 ]
Merriam, C. Vreni [1 ]
机构
[1] RM Alden Res Lab, Culver City, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
BACTEROIDES-FRAGILIS GROUP; INVITRO ACTIVITY; L-627; RESISTANCE; SUSCEPTIBILITY;
D O I
10.1128/AAC.02418-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Biapenem is a carbapenem being developed in combination with RPX7009, a new inhibitor of serine beta-lactamases. Biapenem was tested alone and in combination with fixed concentrations of RPX7009 by agar dilution against 377 recent isolates of anaerobes. A separate panel of 27 isolates of Bacteroides spp. with decreased susceptibility or resistance to imipenem was also tested. Comparator drugs included meropenem, piperacillin-tazobactam, ampicillin-sulbactam, cefoxitin, ceftazidime, metronidazole, clindamycin, and tigecycline plus imipenem, doripenem, and ertapenem for the 27 selected strains. For recent consecutive strains of Bacteroides species, the MIC90 for biapenem-RPX7009 was 1 mu g/ml, with a MIC90 of 4 mu g/ml for meropenem. Other Bacteroides fragilis group species showed a MIC90 of 0.5 mu g/ml for both agents. The MIC(90)s for biapenem-RPX7009 were 0.25 mu g/ml for Prevotella spp., 0.125 mu g/ml for Fusobacterium nucleatum and Fusobacterium necrophorum, 2 mu g/ml for Fusobacterium mortiferum, 0.5 mu g/ml for Fusobacterium varium, <= 0.5 mu g/ml for Gram-positive cocci and rods, and 0.03 to 8 mu g/ml for clostridia. Against 5 B. fragilis strains harboring a known metallo-beta-lactamase, biapenem-RPX7009 MICs were comparable to those of other carbapenems (>= 32 mu g/ml). Against Bacteroides strains with an imipenem MIC of 2 mu g/ml, biapenem-RPX7009 had MICs of 0.5 to 2 mu g/ml, with MICs of 0.5 to 32 mu g/ml for meropenem, doripenem, and ertapenem. For strains with an imipenem MIC of 4 mu g/ml, the MICs for biapenem-RPX7009 were 4 to 16 mu g/ml, with MICs of 8 to >= 32 mu g/ml for meropenem, doripenem, and ertapenem. The inhibitor RPX7009 had no antimicrobial activity when tested alone, and it showed little or no potentiation of biapenem versus anaerobes. Biapenem-RPX7009 showed activity comparable to that of imipenem and was superior to meropenem, doripenem, and ertapenem against imipenem-nonsusceptible Bacteroides spp.
引用
收藏
页码:2620 / 2630
页数:11
相关论文
共 23 条
  • [1] Activity of biapenem (RPX2003) combined with the boronate -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae
    Livermore, David M.
    Mushtaq, Shazad
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (08) : 1825 - 1831
  • [2] Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
    Hecker, Scott J.
    Reddy, K. Raja
    Totrov, Maxim
    Hirst, Gavin C.
    Lomovskaya, Olga
    Griffith, David C.
    King, Paula
    Tsivkovski, Ruslan
    Sun, Dongxu
    Sabet, Mojgan
    Tarazi, Ziad
    Clifton, Matthew C.
    Atkins, Kateri
    Raymond, Amy
    Potts, Kristy T.
    Abendroth, Jan
    Boyer, Serge H.
    Loutit, Jeffrey S.
    Morgan, Elizabeth E.
    Durso, Stephanie
    Dudley, Michael N.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) : 3682 - 3692
  • [3] Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
    Lapuebla, Amabel
    Abdallah, Marie
    Olafisoye, Olawole
    Cortes, Christopher
    Urban, Carl
    Quale, John
    Landman, David
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4856 - 4860
  • [4] High in vitro activity of meropenem/RPX7009 against KPC-producing Enterobacteriaceae in China
    Yang, Qiwen
    Zhang, Ge
    Xu, Zhipeng
    Xu, Yingchun
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S40 - S40
  • [5] High in vitro activity of Meropenem/RPX7009 against KPC-producing Enterobacteriaceae in China
    Yang, Q.
    Zhang, G.
    Xu, Z.
    Xu, Y.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S151 - S151
  • [6] IN-VITRO ACTIVITY OF CEFTRIAXONE COMBINED WITH TAZOBACTAM AGAINST ANAEROBIC-BACTERIA
    WUST, J
    HARDEGGER, U
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (02) : 177 - 181
  • [7] In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
    Hirsch, Elizabeth B.
    Ledesma, Kimberly R.
    Chang, Kai-Tai
    Schwartz, Michael S.
    Motyl, Mary R.
    Tam, Vincent H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3753 - 3757
  • [8] Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
    Lee, Su Young
    Gill, Christian M.
    Nicolau, David P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 2795 - 2800
  • [9] In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii
    Karaoglan, Ilkay
    Zer, Yasemin
    Bosnak, Vuslat Kecik
    Mete, Ayse Ozlem
    Namiduru, Mustafa
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2013, 41 (06) : 1830 - 1837
  • [10] In vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria
    Kato, N
    Tanaka, K
    Kato, H
    Watanabe, K
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) : 357 - 361